Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2006-04-04
2006-04-04
Aulakh, Charanjit S. (Department: 1625)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C548S452000, C548S428000, C546S094000, C540S586000, C514S214020, C514S294000, C514S411000
Reexamination Certificate
active
07022729
ABSTRACT:
Azabicyclic, azatricyclic and azaspirocyclic derivatives of aminocyclohexanes which are systemically-active as NMDA, 5HT3, and nicotinic receptor antagonists, pharmaceutical compositions comprising the same, method of preparation thereof, and method of treating CNS disorders which involve disturbances of glutamatergic, serotoninergic, and nicotinic transmission, treating immunomodulatory disorders, and antimalaria, antitrypanosomal, anti-Borna virus, anti-HSV and anti-Hepatitis C virus activity.
REFERENCES:
patent: 5900227 (1999-05-01), Janzen et al.
patent: 0018077 (1980-10-01), None
patent: 0072438 (1983-02-01), None
patent: 0578560 (1994-01-01), None
patent: 1153973 (1969-06-01), None
patent: 1472334 (1977-05-01), None
patent: WO 92/12149 (1992-07-01), None
patent: WO 94/08964 (1994-04-01), None
patent: WO 96/06081 (1996-02-01), None
patent: WO 00/32600 (2000-06-01), None
patent: WO 01/98253 (2001-12-01), None
Compounds with RNs, 81811-06-05; 81811-07-6; 85984-27-6; 81810-91-5; 81810-90-4 and 81811-09-8 (all disclosed before 1988).
Parsons, et al.,Drug News Perspect., Nov. 1998, 11, 523-569.
Brunson, et al.,Dev. Neurosci., 2001, 23, 31-40 (abstract).
Hadj, et al.,Neurobiol. Dis., 2004, 15, 171-176 (abstract).
Javitt,Mol. Psychiatry, 2004, [Epub ahead of print] (abstract).
Paquet-Durand, et al., 2004, 1011, 33-47 (abstract).
Hare, et al.,Invest. Ophthalmol. Vis. Sci., 2004, 45, 2625-2639 (abstract).
Rosin, et al.,J. Neurochem., 2004, 90, 1173-1185 (abstract).
Dirson, et al.,Metab. Brain Dis., 2002, 17, 77-82 (abstract).
Petri, et al.,Neurosci. Lett., 2004, 360, 170-174 (abstract).
Khodorov,Prog. Biophys. Mol. Biol., 2004, 86, 279-351 (abstract).
Tsai, et al.,Am. J. Psychiatry, 1995, 152, 332-340 (abstract).
Ferrer, et al.,Acta Neuropathol., 2003, 106, 311-318 (abstract).
Greenshaw,TiPS, 1993, 14, 265-270.
Dahlof, et al.,Cephalalgia, 1998, 18, 593-604 (abstract).
Talley,Br. J. Clin. Pharmacol., 2003, 56, 362-369 (abstract).
Deakin,Int. Clin. Psychopharmacol., 1991,6 Suppl 3, 23-31 (abstract).
Meltzer,Schizophr. Bull., 1991, 17, 263-287 (abstract).
Gbadamosi, et al.,Acta. Neurol. Scand., 2001, 104, 308-311 (abstract).
Quick, et al.,Desensitization of Neuronal Nicotinic Receptors, 2002, Wiley Periodicals, Inc., 457-478.
Lloyd, et al.,Life Sciences, 1998, 62, 1601-1606.
Mc Evoy, et al.,Curr. Drug Targets CNS Neurol. Disord., 2002, 1, 433-442 (abstract).
Newhouse, et al.,Curr. Top Med. Chem., 2004, 4, 267-282 (abstract).
Patent Abstracts of Japan, vol. 012, No. 192 (P-712), Jun. 4, 1988.
Beilstein Crossfire Database abstract Accession Nos. 5577766(brn); 5586551(brn); 5615067(brn).
Darwish, et al.,Chemical Abstracts, Accession No. 97:2169.
Chemical Abstracts Chemcats Database, Accession No. 2002:3093676.
Chemical Abstracts, Database Accession No. 121:205227.
Wenk, et al.,European Journal of Pharmacology, 1995, 293, 267-270.
Wenk, et al.,Behavioural Brain Research, 1997, 83, 129-133.
Wenk, et al.,European Journal of Pharmacology, 1998, 347, 183-187.
R.L. Frank, H.K. Hall (1950) J. Am. Chem. Soc. 72:1645-1648.
G.A. Hiegel, P. Burk. (1973) J. Org. Chem. 38:3637-3639.
N.F. Firrell, P.W. Hickmott. (1970) J. Chem. Soc. C:716-719.
G.H. Posner, L.L. Frye. (1984) Isr. J. Chem. 24:88-92.
G.L. Lemiere, T.A. van Osselaer, F.C. Anderweireldt. (1978) Bull. Soc. Chim. Belg. 87:771-782.
H.O. House, J.M. Wilkins. (1976) J. Org. Chem. 41:(25) 4031-4033.
A.R. Greenaway, W.B. Whalley, (1976) J. Chem. Soc. P.T. 1. :1385-1389.
S. Matsuzawa, Y. Horiguchi, E. Nakamura, I. Kuwajima. (1989) Tetrahedron 45:(2) 349-362.
H.O. House, W.F. Fischer. (1968) J. Org. Chem. 33:(3) 949-956.
Chiurdoglu, G., Maquestiau, A. (1954) Bull. Soc. Chim. Belg. 63: 357-378.
Zaidlewicz, M., Uzarewicz A., Zacharewicz, W. (1964) Roczniki Chem. 38: 591-597.
Crossley, A.W., Gilling, C. (1910) J. Chem. Soc. 2218.
Zaidlewicz, M., Uzarewicz, A. (1971) Roczniki Chem. 45: 1187-1194.
Lutz, E.T., van der Maas, J.H. (1981) Spectrochim. Acta, A. 38A: 283.
Lutz, E.T., van der Maas, J.H. (1981) Spectrochim. Acta, A. 37A: 129-134.
Ramalingam K., Balasubramanian, M., Baliah, V. (1972) Indian J. Chem. 10: 366-369.
Hamlin, K.E., Freifelder, M. (1953) J. Am. Chem. Soc. 75: 369-373.
Hassner, A., Fibinger, R., Andisik, D. (1984) J. Org. Chem. 49: 4237-4244.
W. Danysz, C.G. Parsons, I. Bresnik, G. Quack (1995) Drug News Perspect. 8:261-277.
J.D. Leander, R.R. Lawson, P.L., Ornstein, D.M. Zimmerman (1988) Brain Res. 448:115-120.
C.G. Parsons, G. Quack, I. Bresink, L. Baran, E. Przegalinski, W. Kostowski, P. Krzascik, S. Hartmann, W. Danysz (1995). Neuropharmacology 34:1239-1258.
M.A. Rogawski (1993) Trends Pharmacol. Sci. 14:325-331.
Booher J. and Sensenbrenner M. (1972). Neurobiology 2:97-105.
Dichter, M. (1987) Brain Research 149:279.
Danysz Wojciech
Gold Markus
Henrich Markus
Jirgensons Aigars
Kalvinsh Ivars
Aulakh Charanjit S.
Hueschen and Sage
Merz Pharma GmbH & Co. KGAA
LandOfFree
Azabicyclic, azatricyclic and azaspirocyclic derivatives of... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Azabicyclic, azatricyclic and azaspirocyclic derivatives of..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Azabicyclic, azatricyclic and azaspirocyclic derivatives of... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3546120